News

ImmunoPrecise Accelerates the Launch of its European, Full-service, B-cell Facility

Victoria, British Columbia, Canada, July 18th, 2018 – To meet global demand, IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) accelerates the launch of its European B-cell facility expansion at its ModiQuest Research division in Oss, the Netherlands. The new B-cell facility has been launched ahead of schedule, in response to client … Continue reading

IMMUNOPRECISE CLOSES PRIVATE PLACEMENT FINANCING

Victoria, British Columbia, Canada, June 19, 2018 - IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has closed its previously announced non-brokered private placement financing by issuing a total of 875,000 units (“Units”) of ImmunoPrecise at a price of $0.80 per Unit for gross proceeds of $700,000 (the “Financing”).   … Continue reading

IMMUNOPRECISE INCREASES PRIVATE PLACEMENT FINANCING

Victoria, British Columbia, Canada, May 30, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has increased its previously announced non-brokered private placement financing (see news release dated May 29, 2018) to 875,000 units (“Units”) of ImmunoPrecise at a price of $0.80 per Unit for gross proceeds of … Continue reading

IMMUNOPRECISE ANNOUNCES PRIVATE PLACEMENT FINANCING

Victoria, British Columbia, Canada, May 29, 2018 - IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it proposes to complete a non-brokered private placement financing of 750,000 units (“Units”) of ImmunoPrecise at a price of $0.80 per Unit for gross proceeds of $600,000 (the “Financing”). Each Unit will consist of one … Continue reading

Immunoprecise Appoints Jennifer Bath to Board of Directors and Expands Senior Leadership to Further Global Growth

Victoria, British Columbia, Canada, May 24, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that, as part of its annual review of management and board members, it has appointed Jennifer L. Bath, the Chief Executive Officer and President of ImmunoPrecise, as a member of its board of directors. “Under … Continue reading

Immunoprecise Opens U.S. Headquarters in Fargo, North Dakota

Victoria, British Columbia, Canada, May 18, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the opening of its U.S. Headquarters in Fargo, North Dakota. The Fargo-Moorhead (FM) region has a strong and diverse economy with a broad base of entrepreneurs who invest in the regions’ companies.  FM and … Continue reading

IMMUNOPRECISE OPENS NEW FULL SERVICE B-CELL FACILITY

Victoria, British Columbia, Canada, April 27, 2018 - IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the opening of its new, innovative full service B-cell facility offering B-cell screening, sorting and sequencing on a broad range of therapeutically-relevant protein families including GPCRs and other multi-membrane spanning proteins.  The immediate benefits to ImmunoPrecise is that … Continue reading

Immunoprecise Announces Oversubscription To Debenture Financing

Victoria, British Columbia, Canada, April 6, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces it has completed a final tranche to its debenture (the “Debentures”) financing in the principal amount of $250,000.  In total, ImmunoPrecise issued $4,252,000 of Debentures under the entire financing. The Debentures are unsecured, bear interest at a … Continue reading

IMMUNOPRECISE ACQUIRES MODIQUEST RESEARCH BV

Immediately Accretive by Adding EBITDA of Approximately C$750,000 with Increased Synergies, Scale and Efficiency Strategic Acquisition Allows ImmunoPrecise to Provide Comprehensive and Next Generation Antibody Therapeutic Discovery Victoria, British Columbia, Canada, April 6, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) is pleased to announce that it has acquired … Continue reading

Immunoprecies Antibodies Delivers Record Quarterly Revenue of $1.723 Million and Increases Gross Margins To 54%

March 28, 2018 – Victoria, British Columbia.  IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX Venture: IPA, OTC PINK: IPATF) today reports its financial results for the third quarter ended January 31, 2018.  The financial statements and related management’s discussion and analysis (“MD&A”) can be viewed on SEDAR at www.sedar.com. During the three months ended … Continue reading